Rigel Pharmaceuticals Inc. [RIGL] fell -43.02% so far this year. What now?

Rigel Pharmaceuticals Inc. [NASDAQ: RIGL] stock went on an upward path that rose over 11.03% on Wednesday, amounting to a one-week price increase of more than 7.09%. The company report on August 2, 2022 that Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Second quarter TAVALISSE® net product sales of $18.6 million and total revenues of $29.8 million.

Expanded Rigel’s hematology-oncology portfolio by entering into an exclusive license agreement with Forma Therapeutics, Inc. for olutasidenib with an expected launch in 2023.

Over the last 12 months, RIGL stock dropped by -61.28%. The one-year Rigel Pharmaceuticals Inc. stock forecast points to a potential upside of 42.8. The average equity rating for RIGL stock is currently 2.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $247.26 million, with 172.15 million shares outstanding and 170.76 million shares in the current float. Compared to the average trading volume of 6.43M shares, RIGL stock reached a trading volume of 3629278 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Rigel Pharmaceuticals Inc. [RIGL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RIGL shares is $2.64 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RIGL stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Citigroup have made an estimate for Rigel Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 09, 2022. While these analysts kept the previous recommendation, Piper Sandler dropped their target price from $7 to $1. The new note on the price target was released on June 08, 2022, representing the official price target for Rigel Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $6 to $1, while Cantor Fitzgerald kept a Neutral rating on RIGL stock.

The Average True Range (ATR) for Rigel Pharmaceuticals Inc. is set at 0.15, with the Price to Sales ratio for RIGL stock in the period of the last 12 months amounting to 2.79.

RIGL Stock Performance Analysis:

Rigel Pharmaceuticals Inc. [RIGL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.09. With this latest performance, RIGL shares gained by 17.05% in over the last four-week period, additionally sinking by -40.78% over the last 6 months – not to mention a drop of -61.28% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RIGL stock in for the last two-week period is set at 58.44, with the RSI for the last a single of trading hit 62.63, and the three-weeks RSI is set at 54.41 for Rigel Pharmaceuticals Inc. [RIGL]. The present Moving Average for the last 50 days of trading for this stock 1.2453, while it was recorded at 1.4640 for the last single week of trading, and 2.3359 for the last 200 days.

Insight into Rigel Pharmaceuticals Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Rigel Pharmaceuticals Inc. [RIGL] shares currently have an operating margin of -6.01 and a Gross Margin at +98.88. Rigel Pharmaceuticals Inc.’s Net Margin is presently recorded at -12.00.

Return on Equity for this stock declined to -55.63, with Return on Assets sitting at -12.90.

Rigel Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.20.

Rigel Pharmaceuticals Inc. [RIGL] Insider Position Details

There are presently around $210 million, or 93.40% of RIGL stock, in the hands of institutional investors. The top three institutional holders of RIGL stocks are: FMR LLC with ownership of 24,181,804, which is approximately -1.586% of the company’s market cap and around 1.00% of the total institutional ownership; BLACKROCK INC., holding 16,573,646 shares of the stock with an approximate value of $25.03 million in RIGL stocks shares; and VANGUARD GROUP INC, currently with $13.79 million in RIGL stock with ownership of nearly 1.153% of the company’s market capitalization.

Positions in Rigel Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 60 institutional holders increased their position in Rigel Pharmaceuticals Inc. [NASDAQ:RIGL] by around 15,463,136 shares. Additionally, 82 investors decreased positions by around 13,480,520 shares, while 39 investors held positions by with 110,109,826 shares. The mentioned changes placed institutional holdings at 139,053,482 shares, according to the latest SEC report filing. RIGL stock had 11 new institutional investments in for a total of 1,752,489 shares, while 27 institutional investors sold positions of 3,016,746 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here